Clinical Trials Browser

Adenocarcinoma of Lung

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

Clinical Trials

KETO-FDG Lung

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients

EVLC

FONTANA

Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer

BLCIO

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

CRYOMUNE

Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

HARMONIC

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer

RESET

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma

Shared Decision Making in Patients With Lung Cancer

Pathogenic Variants in Genes Associated With Lung Adenocarcinoma

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors

TEG

BIVA-18

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Lymph Node Pathologic Grading Strategy

WSI Based DL for Diagnosing the IASLC Grading System of Lung Adenocarcinoma

Segmentectomy for Solid-dominant Lung Cancer

Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma

Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients

Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter

Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)

BEYOND

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers

Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)

APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch

Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic

Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)

Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%